238 related articles for article (PubMed ID: 31392045)
1. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
Nuñez JE; Donadio M; Filho DR; Rego JF; Barros M; Formiga MN; Lopez R; Riechelmann R
J Gastrointest Oncol; 2019 Aug; 10(4):645-651. PubMed ID: 31392045
[TBL] [Abstract][Full Text] [Related]
2. Somatic
Shell J; Patel D; Powers A; Quezado M; Killian K; Meltzer P; Zhu J; Gaitanidis A; Karzai F; Neychev V; Green P; Kebebew E
J Endocr Soc; 2017 Sep; 1(9):1124-1134. PubMed ID: 29264567
[TBL] [Abstract][Full Text] [Related]
3. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
[No Abstract] [Full Text] [Related]
4. Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.
Zhu L; Ye X; She Y; Liu W; Hasegawa K; Rossi RE; Du Q; Zhai Q
J Gastrointest Oncol; 2024 Apr; 15(2):689-709. PubMed ID: 38756630
[TBL] [Abstract][Full Text] [Related]
5. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.
Keutgen XM; Kumar S; Gara SK; Boufraqech M; Agarwal S; Hruban RH; Nilubol N; Quezado M; Finney R; Cam M; Kebebew E
Cancer; 2018 Feb; 124(3):636-647. PubMed ID: 29149451
[TBL] [Abstract][Full Text] [Related]
7. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition.
Tirosh A; Killian JK; Petersen D; Zhu YJ; Walker RL; Blau JE; Nilubol N; Patel D; Agarwal SK; Weinstein LS; Meltzer P; Kebebew E
J Clin Endocrinol Metab; 2020 Oct; 105(10):3285-94. PubMed ID: 32706863
[TBL] [Abstract][Full Text] [Related]
8. The genetics of neuroendocrine tumors.
Öberg K
Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.
Ruggeri RM; Benevento E; De Cicco F; Fazzalari B; Guadagno E; Hasballa I; Tarsitano MG; Isidori AM; Colao A; Faggiano A;
J Endocrinol Invest; 2023 Feb; 46(2):213-234. PubMed ID: 36038743
[TBL] [Abstract][Full Text] [Related]
11. Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL.
Moore PS; Missiaglia E; Antonello D; Zamò A; Zamboni G; Corleto V; Falconi M; Scarpa A
Genes Chromosomes Cancer; 2001 Oct; 32(2):177-81. PubMed ID: 11550286
[TBL] [Abstract][Full Text] [Related]
12. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
Angelousi A; Kamp K; Kaltsatou M; O'Toole D; Kaltsas G; de Herder W
Neuroendocrinology; 2017; 105(4):394-402. PubMed ID: 28122378
[TBL] [Abstract][Full Text] [Related]
13. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.
Smith D; Lepage C; Vicaut E; Dominguez S; Coriat R; Dubreuil O; Lecomte T; Baudin E; Venat Bouvet L; Samalin E; Santos A; Borie O; Bisot-Locard S; Goichot B; Lombard-Bohas C
Adv Ther; 2022 Jun; 39(6):2731-2748. PubMed ID: 35419649
[TBL] [Abstract][Full Text] [Related]
14. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias.
Marx SJ; Agarwal SK; Kester MB; Heppner C; Kim YS; Skarulis MC; James LA; Goldsmith PK; Saggar SK; Park SY; Spiegel AM; Burns AL; Debelenko LV; Zhuang Z; Lubensky IA; Liotta LA; Emmert-Buck MR; Guru SC; Manickam P; Crabtree J; Erdos MR; Collins FS; Chandrasekharappa SC
Recent Prog Horm Res; 1999; 54():397-438; discussion 438-9. PubMed ID: 10548885
[TBL] [Abstract][Full Text] [Related]
15. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract][Full Text] [Related]
16. A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.
Soczomski P; Jurecka-Lubieniecka B; Krzywon A; Cortez AJ; Zgliczynski S; Rogozik N; Oczko-Wojciechowska M; Pawlaczek A; Bednarczuk T; Jarzab B
Front Endocrinol (Lausanne); 2021; 12():681013. PubMed ID: 34122352
[TBL] [Abstract][Full Text] [Related]
17. Systematic comparison of sporadic and syndromic pancreatic islet cell tumors.
Erlic Z; Ploeckinger U; Cascon A; Hoffmann MM; von Duecker L; Winter A; Kammel G; Bacher J; Sullivan M; Isermann B; Fischer L; Raffel A; Knoefel WT; Schott M; Baumann T; Schaefer O; Keck T; Baum RP; Milos I; Muresan M; Peczkowska M; Januszewicz A; Cupisti K; Tönjes A; Fasshauer M; Langrehr J; von Wussow P; Agaimy A; Schlimok G; Lamberts R; Wiech T; Schmid KW; Weber A; Nunez M; Robledo M; Eng C; Neumann HP; ;
Endocr Relat Cancer; 2010 Dec; 17(4):875-83. PubMed ID: 20660572
[TBL] [Abstract][Full Text] [Related]
18. Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations.
Liu E; Marincola P; Oberg K
Therap Adv Gastroenterol; 2013 Sep; 6(5):412-9. PubMed ID: 24003341
[TBL] [Abstract][Full Text] [Related]
19. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib.
Vinik AI; Raymond E
Therap Adv Gastroenterol; 2013 Sep; 6(5):396-411. PubMed ID: 24003340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
